PML-RARA is a questionable disease in the field of blood tumours, clinical performance is complex and often involves multi-system congestion. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological evaluation.
The platform can help to combine a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of acute myeloid leukemia. 17) Treatment regimens for PML-RARA need to be individualized, typically including multidimensional management of drug therapy, rehabilitation interventions, regular follow-up, and more.
In recent years, with the development of targeted therapy, immune regulation therapy, and precision medicine, significant improvements have been made in many previously difficult-to-treat blood tumour diseases. Treatment needs to be closely monitored for therapeutic efficacy and adverse reactions, and timely adjusted according to changing conditions. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of blood oncology to provide the following services to patients: 1.
Remote pre-diagnosis: pre-examination of medical history, precise diagnostic directions and medical advice by a team of experts; 2. Interviews in China: arranging face-to-face diagnosis with authoritative experts, developing personalized treatment programs; 3. Full-service: one-stop services: providing medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.